COMMUNIQUÉS West-GlobeNewswire

Hydropothecary choisit Shopify pour ses services de commerce électronique destinés aux marchés du cannabis à fins médicales et récréatives
20/03/2018
GATINEAU, Québec, 20 mars 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (TSX CROISSANCE:THCX) (« Hydropothecary ») a conclu une entente avec Shopify, l’une des entreprises de commerce en ligne les plus respectées [...]
Carolina Complete Health Network Announces Public Offering of Class P Common Stock
20/03/2018
RALEIGH, N.C., March 20, 2018 (GLOBE NEWSWIRE) -- Carolina Complete Health Network, Inc. (CCHN), a company formed to build and support a patient-focused, physician-led Medicaid health network, today announced that it [...]
PotNetwork Holding, Inc. Senior Advisor Bruce BarrenBarren to appear on National Radio and Webcast Today, Tuesday March 20th, 2018
20/03/2018
FT LAUDERDALE, Fla., March 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holding, Inc. (OTC Pink:POTN) Today, Tuesday the 20th of March in 2018, PotNetwork Holding Inc. Senior Advisor Bruce Barren is [...]
AC Immune reports full-year 2017 financial results - successful first year as a public company
20/03/2018
Lausanne, Switzerland, March 20, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results [...]
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer
20/03/2018
Lugano, Switzerland, March 20, 2018 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announced that the first patient has been enrolled in a Phase 3b study to assess the [...]
Herantis Pharma's Annual Report 2017 published
20/03/2018
Herantis Pharma's Annual Report 2017 published Herantis Pharma Plc Company release 20 March 2018 at 9:00 am Herantis Pharma Plc's Annual Report for the year 2017 has been published today. The Annual Report contains [...]
Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data
20/03/2018
Press Release 20 March 2018 Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing [...]
Shire plc : New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism
20/03/2018
New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism - Clinical and real-world data on chronic hypoparathyroidism provides new insights [...]
Motif Bio Update on NDA Submission for Iclaprim
20/03/2018
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and [...]
PCI Biotech: Full year 2017 report - a transformative year
20/03/2018
Oslo (Norway), 20 March 2018 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its full year result. Please find enclosed the full year 2017 presentation. 2017 was a year of [...]
Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
20/03/2018
Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development of novel implantable and [...]
Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy
20/03/2018
Pratteln, Switzerland, March 20, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports the Group's audited financial results for 2017. Net revenues from sales of lead product Raxone® (idebenone) increased by 21% compared [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
20/03/2018
REGULATED INFORMATION GHENT, Belgium, 20 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Helix BioPharma Corp. Announces Fiscal Second Quarter 2018 Results
20/03/2018
RICHMOND HILL, Ontario, March 19, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP ) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates [...]
PCI Biotech: Annual Report 2017
19/03/2018
Oslo (Norway), March 19, 2018 The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2017 and the report is attached. The Annual Report 2017 is also available on the company's website www. [...]
Immunovaccine Researchers to Present New Preclinical Data at AACR Annual Meeting 2018
19/03/2018
HALIFAX, Nova Scotia, March 19, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Company will present research on the anti-cancer [...]
CohBar, Inc. to Announce 2017 Fourth Quarter Financial Results and Host Conference Call for Shareholders on April 2, 2018
19/03/2018
MENLO PARK, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR ) (TSXV:COB.U), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, [...]
Brainsway Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
19/03/2018
Increased market demand and new leasing model continue to generate significant sales growth Total minimum committed revenue projection is record $27 million for year-end 2017, up 142% versus year-end 2016 Strong balance [...]
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
19/03/2018
- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic Anemia (AIHA) and [...]

Pages